Skip to content

XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

Tag: HIV

August 31, 2026

A New Milestone in HIV Care: FDA Approves Bixlenvo

NASDAQ: $GILD A New Option for HIV Management The landscape of HIV treatment continues to evolve, offering more flexibility for those living with the virus. The FDA has officially approved Bixlenvo, a new medication combining bictegravir and lenacapavir, specifically designed for adults who are already virologically suppressed. Understanding Bixlenvo Bixlenvo is indicated for use in…

FDA Acceptance

$GILD, Antiretroviral Therapy, Bictegravir, Bixlenvo, FDA Approval, HIV
August 28, 2026

A Major Milestone: FDA Approves Tivicay PD for Infants Living with HIV

A New Option for the Youngest Patients ViiV Healthcare has reached a significant milestone in pediatric HIV care. The U.S. Food and Drug Administration (FDA) has officially approved Tivicay PD (dolutegravir), a dispersible tablet formulation designed specifically for infants and children living with HIV who weigh at least 2 kg. Why This Approval Matters Prior…

FDA Acceptance

FDA Approval, HIV, pediatric HIV, Tivicay PD, ViiV Healthcare

© XBioReport.com

Disclaimer: This site is for information only. Not investment advice.

Get FREE Biotech Stock Catalyst Reports

Email

Notify me about related content and special offers.

Yes No

If you opt in above, we use this information to send related content, discounts, and other special offers.